Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia - A Single-arm, Non-interventional Retrospective Chart Review Study

Novo Nordisk A/S1 site in 1 country175 target enrollmentMarch 22, 2022

ConditionsDiabetes Mellitus, Type 2

InterventionsIDegLira

DrugsIDegLira

Overview

Phase: Not Applicable
Intervention: IDegLira
Conditions: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Enrollment: 175
Locations: 1
Primary Endpoint: Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c)
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate the glycaemic control and other clinical parameters in adult patients previously treated with basal insulin (with or without OADs) and switched to IDegLira in real-world clinical practice in Colombia.

Registry

clinicaltrials.gov

Start Date

March 22, 2022

End Date

July 15, 2022

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Novo Nordisk A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Arms & Interventions

IDegLira

Adult patients with T2D who have initiated treatment with IDegLira a minimum of 26 weeks

Intervention: IDegLira

Outcomes

Primary Outcomes

Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c)

Time Frame: From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation

Percentage point

Secondary Outcomes

Comparison between the daily dose of basal insulin and IDegLira(From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation)
Change in absolute body weight(From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation)